Abstract
Tubulocystic carcinoma of the kidney (TC-RCC) is a rare renal tumor and has been recently included as a distinct entity in WHO classification of renal neoplasms. We report the case of a patient with metastatic tubulocystic RCC whose disease progressed through standard of care treatment for nonclear RCC. However, genetic analysis revealed a germline pathogenic variant of fumarate hydratase (FH) gene, and the patient had a sustained and durable response to pazopanib.
Original language | English |
---|---|
Pages (from-to) | 240-248 |
Number of pages | 9 |
Journal | Case Reports in Oncology |
Volume | 16 |
Issue number | 1 |
DOIs | |
Publication status | Published - Apr 14 2023 |
ASJC Scopus subject areas
- Oncology